Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction

Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.

NCT Number	NCT07753772
Lead Sponsor	Peking University First Hospital
Conditions	Ureteral Stricture, Dexmedetomidine, Esketamine, Depressive Symptoms, Anxiety
Enrollment	658 participants
Start Date	2026-08
Primary Completion	2029-07 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-14